Indicated for: prevention of transplant rejection
Substance: basiliximab (monoclonal antibody)
ATC: L04AC02 (Antineoplastic and immunomodulating agents | Immunosuppressants | Interleukin inhibitors)
Basiliximab is a monoclonal antibody used to prevent acute graft rejection in patients who have undergone kidney transplantation. It works by blocking the interleukin-2 receptor (IL-2R) on activated T lymphocytes, thereby inhibiting the immune response that could lead to organ rejection.
Basiliximab is administered intravenously, usually in two doses: the first before transplantation and the second a few days after the procedure. It is used in combination with other immunosuppressive drugs, such as cyclosporine and corticosteroids, to enhance treatment efficacy.
Common side effects include nausea, fever, infections, and injection site reactions. In rare cases, severe allergic reactions or opportunistic infections may occur. Careful monitoring of the patient's condition is essential during treatment.
Basiliximab is an important therapeutic option for kidney transplant patients, helping to reduce the risk of acute rejection and improve long-term outcomes.